Skip to main content
MNPR
NASDAQ Life Sciences

Monopar Therapeutics Reports Q1 2026 Financials, Extends Cash Runway to End of 2027, ALXN1840 NDA Expected Mid-2026

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$58.91
Mkt Cap
$394.234M
52W Low
$28.4
52W High
$105
52W Position info
107% above low
Off High info
44% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

MNPR has more than doubled off its 52-week low of $28.4.

Summary

Monopar Therapeutics reported Q1 2026 results, showing increased R&D spend and a cash runway through December 2027, with its lead candidate ALXN1840's NDA submission now targeted for mid-2026.


Key Events · Earnings and Guidance · MNPR

  • Strong Cash Position and Extended Runway

    The company reported $137.5 million in cash, cash equivalents, and investments as of March 31, 2026, and estimates these funds will be sufficient to meet obligations through December 31, 2027.

  • Increased Research and Development Expenses

    R&D expenses significantly increased to $3.49 million for Q1 2026, up from $1.64 million in Q1 2025, reflecting active advancement of its clinical programs.

  • ALXN1840 NDA Submission Timeline Update

    The NDA submission for ALXN1840, its lead candidate for Wilson disease, is now expected in mid-2026, following continued dialogue with the FDA.

  • Ongoing Radiopharmaceutical Pipeline Progress

    Monopar continues to advance its MNPR-101-Zr (Phase 1 imaging) and MNPR-101-Lu (Phase 1a therapeutic) clinical trials, with MNPR-101-Ac in late preclinical development.


Analysis · MNPR · Life Sciences

Monopar Therapeutics' latest quarterly report provides an updated financial snapshot and key pipeline developments. The company maintains a strong cash position, extending its operational runway through December 2027, which is crucial for a clinical-stage biotech. The increased R&D expenses reflect active development across its ALXN1840 and radiopharmaceutical programs. While the ALXN1840 NDA submission is now anticipated in mid-2026, indicating a slight delay, the ongoing positive clinical data and constructive dialogue with the FDA suggest continued progress towards regulatory approval.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MNPR was trading at $58.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $394.2M. The 52-week trading range was $28.40 to $105.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MNPR - Latest Insights

MNPR
Nov 12, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
7
MNPR
Nov 12, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
MNPR
Aug 12, 2026, 9:30 AM EDT
Filing Type: 8-K
Importance Score:
7
MNPR
Aug 12, 2026, 9:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
MNPR
Aug 12, 2026, 9:30 AM EDT
Source: GlobeNewswire
Importance Score:
8